Advertisement

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.